SANDOZ NEORAL MICROEMULSION CYCLOSPORINE ALRIGHT FOR SANDIMMUNE PATIENTS, BUT PHASE IV PEDIATRIC STUDIES NECESSARY, FDA ADVISORY COMMITTEE DECIDES
Sandoz' Neoral microemulsion formulation of cyclosporine, created to be better absorbed than the company's current cyclosporine product Sandimmune, can be safely used in those populations now treated with Sandimmune, FDA's Antiviral Drugs Advisory Committee Subcommittee on Immunosuppression concluded at its March 31 meeting in Silver Spring, Md.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth